<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25800" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neuroleptic Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ameer</surname>
            <given-names>Muhammad Atif</given-names>
          </name>
          <aff>Suburban Community Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Atif Ameer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25800.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Neuroleptics,&#x000a0;also known as antipsychotic medications, are used for the treatment and management of symptoms associated with various psychiatric disorders. Neuroleptic medications are categorized into 2 classes&#x02014;first-generation or "typical" antipsychotics and second-generation or "atypical" antipsychotics.&#x000a0;First-generation antipsychotics were initially developed in the 1950s primarily for the treatment of psychosis, such as schizophrenia. In addition to psychotic illnesses, first-generation antipsychotics have been approved by the US Food and Drug Administration (FDA) for treating and managing acute mania, agitation, bipolar disorder, Tourette syndrome, and hyperactivity. Furthermore, second-generation antipsychotics have also been FDA-approved to treat and manage psychosis and treatment-resistant schizophrenia, bipolar disorder, schizoaffective disorder, agitation, and irritability or agitation.</p>
        <p>Notably, beyond their FDA-approved uses,&#x000a0;both first- and second-generation antipsychotics are used in various neuropsychiatric conditions, which are currently considered off-label. These conditions include attention-deficit hyperactivity disorder, behavioral disturbances in dementia, geriatric agitation, depression, eating disorders, personality disorders, insomnia, generalized anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, and substance use and dependence disorders.&#x000a0;For many of these conditions, the evidence is inconclusive, and clinicians should use their judgment when considering the prescription of neuroleptics.&#x000a0;Neuroleptic medications inhibit dopamine receptors in the nervous system.&#x000a0;This activity examines the indications and contraindications of neuroleptics, emphasizing the importance of the interprofessional healthcare team in ensuring safer prescription practices.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for neuroleptic medications in treating various psychiatric disorders, including schizophrenia, bipolar disorder, and acute agitation.</p></list-item><list-item><p>Screen patients for potential contraindications or risk factors before initiating neuroleptic treatment, including cardiac conditions, metabolic disorders, and substance use disorders.</p></list-item><list-item><p>Apply appropriate strategies to manage and mitigate common adverse effects of neuroleptic medications, including metabolic syndrome, extrapyramidal symptoms, and sedation.</p></list-item><list-item><p>Collaborate with other healthcare professionals, including psychiatrists, pharmacists, and nurses, to ensure comprehensive and coordinated care for patients receiving neuroleptic medications.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25800&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25800">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25800.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Neuroleptics,&#x000a0;also known&#x000a0;as antipsychotic medications, are&#x000a0;used&#x000a0;for the treatment and management of symptoms associated with various psychiatric disorders.&#x000a0;Neuroleptic medications are categorized into&#x000a0;2&#x000a0;classes&#x02014;first-generation or "typical" antipsychotics and second-generation or "atypical" antipsychotics." Neuroleptic medications inhibit dopamine receptors in the nervous system.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>First-generation antipsychotics were initially developed in the 1950s primarily for the treatment of psychosis, such as schizophrenia.<xref ref-type="bibr" rid="article-25800.r1">[1]</xref> In addition to psychotic illnesses, they have been approved by the US Food and Drug Administration (FDA) for treating and managing acute mania, agitation, bipolar disorder, Tourette syndrome, and hyperactivity. Due to the poorly tolerated and often irreversible adverse effects of first-generation antipsychotics, the second class of neuroleptics, also referred to as second-generation antipsychotics, was established in the 1980s. These second-generation antipsychotics have been FDA-approved to treat and manage psychosis and treatment-resistant schizophrenia, bipolar disorder, schizoaffective disorder, agitation, and irritability or agitation. By 2001, 96% of the neuroleptics prescribed to new users were second-generation.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Beyond their FDA-approved uses,&#x000a0;both first- and second-generation antipsychotics are used in various neuropsychiatric conditions, which are currently considered off-label. These conditions include attention-deficit hyperactivity disorder, behavioral disturbances in dementia, geriatric agitation, depression, eating disorders, personality disorders, insomnia, generalized anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, and substance use and dependence disorders. For many of these conditions, the evidence is inconclusive, and clinicians should use their judgment when considering the prescription of neuroleptics. With increasing off-label use and high costs, evaluating the evidence for their emergent use is important.<xref ref-type="bibr" rid="article-25800.r2">[2]</xref><xref ref-type="bibr" rid="article-25800.r3">[3]</xref><xref ref-type="bibr" rid="article-25800.r4">[4]</xref><xref ref-type="bibr" rid="article-25800.r5">[5]</xref>&#x000a0;</p>
        <p>Lumateperone, an atypical antipsychotic, possesses a distinctive pharmacodynamic profile that holds clinical implications for addressing both negative and positive symptoms of schizophrenia.<xref ref-type="bibr" rid="article-25800.r6">[6]</xref></p>
        <p><bold>FDA-approved first-generation antipsychotics (conventional antipsychotics):</bold>&#x000a0;The FDA-approved first-generation antipsychotics (conventional antipsychotics) include chlorpromazine, droperidol, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, perphenazine, pimozide, thioridazine, thiothixene, and trifluoperazine.<xref ref-type="bibr" rid="article-25800.r7">[7]</xref></p>
        <p><bold>FDA-approved second-generation&#x000a0;antipsychotics (atypical antipsychotics):</bold> The FDA-approved second-generation antipsychotics (atypical antipsychotics) include aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone, and lumateperone.<xref ref-type="bibr" rid="article-25800.r8">[8]</xref></p>
      </sec>
      <sec id="article-25800.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>In first-generation antipsychotic medications, the postsynaptic blockade of dopamine D2 receptors in the mesolimbic system of the central nervous system (CNS) is the mechanism of action. Evidence suggests strong antagonism of D2 receptors in both striatal and cortical areas, a higher association between D2 receptor binding and its potency, and a consistent requirement of 65% D2 receptor occupancy for antipsychotic efficacy in functional imaging studies. The nonspecific localization of dopamine binding throughout the CNS is consistent with the risk of movement disorders (drug-induced Parkinsonism) and hyperprolactinemia.<xref ref-type="bibr" rid="article-25800.r9">[9]</xref><xref ref-type="bibr" rid="article-25800.r10">[10]</xref><xref ref-type="bibr" rid="article-25800.r11">[11]</xref></p>
        <p>Second-generation antipsychotics differ from first-generation by transiently occupying D2 receptors, followed by rapid dissociation,&#x000a0;facilitating normal dopamine neurotransmission. They also have fast D2 dissociation, antagonistic properties on the 5HT2A receptor, and 5HT1A agonism. Second-generation antipsychotics have fewer&#x000a0;adverse&#x000a0;effects and are generally considered safe in adult and older populations. These differences account for the normal prolactin levels, lessened cognitive deficits, and preclusion of extrapyramidal symptoms.<xref ref-type="bibr" rid="article-25800.r12">[12]</xref></p>
      </sec>
      <sec id="article-25800.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms, Strengths, and Adult Dosage</bold>
</p>
        <p>Most first-generation antipsychotic medications are available in oral formulations. Several are also available in injectable intramuscular (IM) formulations, which are useful in treating psychotic agitation. Clinicians sometimes use intravenous (IV) formulations of haloperidol and droperidol to treat psychosis or delirium in acute medical settings. Long-acting, decanoate preparations of haloperidol and fluphenazine are deliverable via&#x000a0;IM injection&#x000a0;1 to&#x000a0;2 times per month, which is useful for nonadherent patients with daily oral dosing.</p>
        <p>Second-generation antipsychotics are also available in oral formulations. Additionally, aripiprazole is known as an&#x000a0;IM injection (immediate release) for use in acute settings, and olanzapine, risperidone, paliperidone, and aripiprazole are available in the form of long-acting injectables for use in nonadherent patients. The injectable form is for use in older and non-compliant patients, so a steady dose of the antipsychotic is available without any withdrawal effects.<xref ref-type="bibr" rid="article-25800.r13">[13]</xref></p>
        <p>The dosage of first-generation or typical antipsychotic drugs depends upon the indication and clinical condition. This class overview article will not cover specific dosing of individual agents.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Phenothiazines are established causes of drug-induced liver disease, typically leading to cholestatic injury within 1 to 4 weeks of treatment initiation. Chlorpromazine is associated with hepatotoxicity and "Thorazine&#x000a0;jaundice." Among atypical antipsychotics, olanzapine and clozapine are linked to hepatotoxicity. Risperidone and quetiapine&#x000a0;are modestly related to drug-induced liver injury (DILI), while aripiprazole and ziprasidone are&#x000a0;associated&#x000a0;with a smaller number of DILI, and the evidence is unclear.<xref ref-type="bibr" rid="article-25800.r14">[14]</xref></p>
        <p><bold>Renal impairment:</bold> First-generation antipsychotics are generally considered safe in chronic kidney disease (CKD) without requiring dose adjustments, including haloperidol. However, phenothiazines (such as chlorpromazine) carry a risk of hypotension in CKD. The hepatic metabolism of most second-generation antipsychotics&#x000a0;makes them relatively safe for patients&#x000a0;with renal disorders. In mild-to-moderate renal dysfunction, the majority of antipsychotics are considered safe. However, potential dosage modifications may be needed for end-stage renal disease patients. Caution is warranted when utilizing clozapine, lurasidone, olanzapine, risperidone, quetiapine, and paliperidone. Furthermore, it is advisable to refrain from&#x000a0;prescribing&#x000a0;depot formulations of typical and atypical antipsychotics in the presence of renal impairment.<xref ref-type="bibr" rid="article-25800.r15">[15]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Systematic reviews on second-generation antipsychotic medications have indicated that olanzapine and quetiapine are acceptable during lactation. Studies indicate that olanzapine has low relative infant dose (RID) values. The available data are limited but suggest relatively low RID values for quetiapine and ziprasidone, moderately low RID values for risperidone/paliperidone and aripiprazole, and comparatively higher RID values for amisulpride.<xref ref-type="bibr" rid="article-25800.r16">[16]</xref><xref ref-type="bibr" rid="article-25800.r17">[17]</xref><xref ref-type="bibr" rid="article-25800.r18">[18]</xref></p>
        <p><bold>Pregnancy considerations:</bold> According to the American Psychiatric Association (APA) Guidelines for schizophrenia, the objective of antipsychotic management in pregnant women is to control symptoms using the lowest therapeutic dose effectively. Changing medications is generally discouraged if symptoms are well managed. Antipsychotic agents can cross the placental barrier. The maximal susceptibility to congenital anomalies is from the third to the eighth gestational week. Discontinuing these neuroleptic medications after the eighth week does not significantly decrease the risk of congenital malformations; consider risk-benefit analysis on an individual patient basis. Observational investigations suggest the marginal likelihood of congenital malformations associated with most antipsychotics, including second-generation antipsychotics. Administering antipsychotic drugs during the third trimester may precipitate withdrawal symptoms; close monitoring of neonates is recommended.<xref ref-type="bibr" rid="article-25800.r7">[7]</xref><xref ref-type="bibr" rid="article-25800.r19">[19]</xref></p>
        <p><bold>Pediatric patients:</bold> The Key Potentially Inappropriate Drugs in Pediatrics (KIDS) list includes chlorpromazine, fluphenazine, haloperidol, perphenazine, pimozide, prochlorperazine, promethazine, and trifluoperazine. These antipsychotics are associated with adverse effects such as acute dystonia and dyskinesia.&#x000a0;IV administration increases the risk of respiratory depression, extravasation, and potentially fatal outcomes. Antipsychotics should be used with caution in pediatric patients.<xref ref-type="bibr" rid="article-25800.r20">[20]</xref></p>
        <p><bold>Older patients:</bold> The American Geriatric Society Beers Criteria 2023 advises against using drugs with substantial anticholinergic properties, such as chlorpromazine, clozapine, olanzapine, and perphenazine.<xref ref-type="bibr" rid="article-25800.r21">[21]</xref></p>
      </sec>
      <sec id="article-25800.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>In addition to their activity&#x000a0;at D2 receptors, first-generation antipsychotics&#x000a0;exert significant effects on 5-HT2A, alpha-1, histaminic, and muscarinic receptors, corresponding to adverse effect&#x000a0;profiles. These pharmacological differences are the basis for classifying first-generation antipsychotics as either high or low-potency medications.<xref ref-type="bibr" rid="article-25800.r22">[22]</xref><xref ref-type="bibr" rid="article-25800.r23">[23]</xref><xref ref-type="bibr" rid="article-25800.r24">[24]</xref></p>
        <p>The high-potency, first-generation antipsychotics, such as&#x000a0;fluphenazine,&#x000a0;trifluoperazine,&#x000a0;haloperidol, loxapine,&#x000a0;pimozide,&#x000a0;perphenazine, and thiothixene, are dosed in the range of&#x000a0;1 to&#x000a0;10&#x000a0;mg and display low activity at histaminic and muscarinic receptors. They are associated with weight gain, sedative effects, or anticholinergic activity and have a high risk of extrapyramidal adverse effects, including dystonia, bradykinesia, rigidity, and tremor, neuroleptic malignant syndrome (NMS), and tardive dyskinesia due to dopamine receptor hypersensitivity and hyperprolactinemia.</p>
        <p>Low-potency, first-generation antipsychotics such as chlorpromazine and thioridazine are dosed in hundreds of milligrams and have high histaminic and muscarinic activity with a corresponding heightened prevalence of dizziness, sedation, and anticholinergic effects (dry mouth, urinary retention, and constipation), but carry a lower risk of extrapyramidal adverse effects.</p>
        <p>Due to the fewer extrapyramidal and anticholinergic effects, second-generation antipsychotics are the first-line treatment for psychotic disorders such as schizophrenia. Second-generation antipsychotics have correlations with weight gain, type 2 diabetes, metabolic syndrome, fatigue/drowsiness, sedation, and QTc prolongation. Among the second-generation antipsychotics, clozapine is most effective in reducing psychotic symptoms and suicidality. The use of clozapine is mostly for treatment-resistant schizophrenia. However, due to the significant adverse effect of agranulocytosis, clozapine is reserved for severe cases of psychotic disorders after a patient has had an insufficient response to&#x000a0;2 adequate trials of other antipsychotic medications.<xref ref-type="bibr" rid="article-25800.r25">[25]</xref></p>
      </sec>
      <sec id="article-25800.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Because of their wide-ranging adverse effects, neuroleptic medications may cause or aggravate some conditions. They are contraindicated in patients with liver damage, coronary artery disease, cerebrovascular disease, parkinsonism, bone marrow depression (such as&#x000a0;clozapine), severe hypotension or hypertension, coma, or severely depressed states. They should be used cautiously in people with seizure disorders, diabetes mellitus, glaucoma, prostatic hypertrophy, peptic ulcer disease, and chronic respiratory diseases.<xref ref-type="bibr" rid="article-25800.r26">[26]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>The FDA has warned&#x000a0;about antipsychotic medications, cautioning against their use in older patients with dementia-related psychosis due to an increased mortality risk.<xref ref-type="bibr" rid="article-25800.r7">[7]</xref>&#x000a0;A study also suggests a possible link between reduced antipsychotic use and higher utilization of antiepileptic and opioid medications,&#x000a0;with&#x000a0;increased&#x000a0;cardiovascular event rates raising concerns about unintended consequences. Further research is needed to validate these findings.<xref ref-type="bibr" rid="article-25800.r21">[21]</xref><xref ref-type="bibr" rid="article-25800.r27">[27]</xref></p>
      </sec>
      <sec id="article-25800.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>For first-generation (typical) antipsychotic drugs, therapeutic drug monitoring is often recommended for compliance control and to minimize extrapyramidal reactions by maintaining chronic exposure at appropriate blood levels. In the case of clozapine, therapeutic drug monitoring is essential due to safety concerns regarding agranulocytosis, myocarditis, and seizures. Physicians should obtain a complete blood count (CBC) and absolute neutrophil count before and after initiating clozapine treatment. Olanzapine carries a risk of postinjection delirium/sedation syndrome,<xref ref-type="bibr" rid="article-25800.r28">[28]</xref> necessitating administration in a registered healthcare facility with immediate access to emergency response services. Patients receiving olanzapine injections should be observed for at least 3 hours after administering the injection and accompanied upon discharge.<xref ref-type="bibr" rid="article-25800.r7">[7]</xref></p>
        <p>With second-generation antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole), the rationale for monitoring drug levels is debatable. Positron emission tomography (PET) enables measurement of the occupancy of dopamine D2 receptors and reveals receptor occupancy interacts better with plasma concentrations than with doses of the antipsychotics. A&#x000a0;consistent 65% D2 receptor occupancy&#x000a0;is required for antipsychotic efficacy in functional imaging studies. Regarding plasma levels related to therapeutic effects, established ideal concentrations for clozapine are (350 to&#x000a0;600 ng/mL), risperidone (20 to&#x000a0;60 ng/mL), and olanzapine (20 to 80 ng/mL), but not for the other second-generation antipsychotics. In conclusion, the evidence is growing that drug monitoring may improve efficacy and safety in patients treated with the new antipsychotic drugs, especially when patients do not respond or develop adverse effects under therapeutic doses.</p>
      </sec>
      <sec id="article-25800.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>An isolated overdose of neuroleptics is rarely fatal. Toxicity results from the blockade of some or all of the following receptors, including dopamine (extrapyramidal symptoms), alpha-1 (orthostatic hypotension, reflex tachycardia), muscarinic (anticholinergic symptoms), and histaminic (sedation).<xref ref-type="bibr" rid="article-25800.r29">[29]</xref></p>
        <p>The extrapyramidal symptoms include acute dystonia (tongue protrusion, facial grimacing, trismus, and oculogyric crisis) and akathisia (feeling of inner restlessness). The anticholinergic effects include tachycardia, dry mucous membranes, dry skin, decreased bowel sounds, and delirium. These symptoms&#x000a0;can be managed&#x000a0;with diphenhydramine&#x000a0;25 to 50 mg IV/IM or benztropine&#x000a0;1 to 2 mg IV/IM. Electrocardiogram (ECG) changes such as sinus tachycardia and QT prolongation can result from neuroleptic toxicity. With QTc prolongation of more than 500 ms, treatment with&#x000a0;magnesium 2 to 4 g IV over 10 minutes is indicated.</p>
        <p>The most life-threatening emergency associated with the use of neuroleptics is NMS.<xref ref-type="bibr" rid="article-25800.r30">[30]</xref><xref ref-type="bibr" rid="article-25800.r31">[31]</xref> This syndrome can occur from a single, increasing, or the same dose.&#x000a0;NMS is mostly associated with first-generation antipsychotics. Still, it can also occur to a lesser degree with second-generation antipsychotics, antiemetics (metoclopramide and promethazine), and the withdrawal of antiparkinson medication. Symptoms typically develop over 1 to 3 days, mortality rates are 5% to 20%, and the majority of deaths occur due to complications of muscle rigidity. Clinical characteristics of&#x000a0;NMS include the tetrad of altered mental status, muscular rigidity, hyperthermia, and autonomic instability. Management involves stopping the causative agent, supportive care with fluid resuscitation and cooling measures, and directed medical therapy of dantrolene (skeletal muscle relaxant) at 0.25 to&#x000a0;2 mg/kg IV every 6 to 12 hours with a max dose of 10 mg/kg/d or bromocriptine (dopamine agonist) at 2.5 mg by mouth every 6 to 8 hours with a maximum dose 40 mg/d.<xref ref-type="bibr" rid="article-25800.r32">[32]</xref>&#x000a0;In May 2023, the FDA&#x000a0;granted supplemental approval to Brexpiprazole&#x000a0;for treating agitation associated with Alzheimer disease, the leading cause of dementia.<xref ref-type="bibr" rid="article-25800.r32">[32]</xref></p>
      </sec>
      <sec id="article-25800.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Neuroleptic drugs offer benefits in managing behavioral disorders. Although the newer generation is considered safer, adverse effects such as weight gain, hyperlipidemia, and metabolic syndrome can still occur. All interprofessional healthcare team members should promote healthy lifestyle habits for patients, including a balanced diet, regular exercise, and smoking cessation. Regular monitoring of body weight, ECG, and lipid levels is essential. However, due to the nature of the illness and potential adverse effects, medication compliance tends to be low.<xref ref-type="bibr" rid="article-25800.r33">[33]</xref>&#x000a0;</p>
        <p>Patients should be educated about the importance of compliance and the adverse effects.&#x000a0;Prescribing clinicians must carefully examine each patient's case to decide if they will benefit from therapy with neuroleptic medications. Nurses should provide counseling on dosing and regarding potential adverse events, which the pharmacist can also reinforce. Pharmacists should also examine the patient's medication record to determine the potential for drug-drug interactions and report any possible issues to the prescriber. This interprofessional approach will increase therapeutic benefit with a lower potential for adverse events.</p>
        <p>In patients receiving high-risk medications such as neuroleptics, a collaborative monitoring approach involving psychiatrists and internists is crucial for detecting potential signs of serious adverse effects like agranulocytosis, metabolic syndrome, extrapyramidal syndrome, and QT interval prolongation. Emergency clinicians should promptly stabilize patients in cases of neuroleptic malignant syndrome (NMS) or overdose, with supportive care provided under the supervision of critical care specialists. A study assessing the impact of collaborative medication management involving nurses and physicians on patient outcomes in acute psychiatric care for individuals with schizophrenia revealed significant improvements in social functioning among patients in the physician-nurse collaborative group, along with increased medication acceptance.<xref ref-type="bibr" rid="article-25800.r34">[34]</xref>&#x000a0;Effective communication and collaboration among clinicians, nurses, and pharmacists within an interprofessional healthcare team is essential for optimizing patient outcomes associated with neuroleptic medications.</p>
      </sec>
      <sec id="article-25800.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25800&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25800">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25800/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25800">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25800.s11">
        <title>References</title>
        <ref id="article-25800.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cussotto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dinan</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Cryan</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Psychotropics and the Microbiome: a Chamber of Secrets&#x02026;.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>2019</year>
            <month>May</month>
            <volume>236</volume>
            <issue>5</issue>
            <fpage>1411</fpage>
            <page-range>1411-1432</page-range>
            <pub-id pub-id-type="pmid">30806744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rawat</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Ramasubbu</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.</article-title>
            <source>Therapie</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>74</volume>
            <issue>6</issue>
            <fpage>599</fpage>
            <page-range>599-609</page-range>
            <pub-id pub-id-type="pmid">31053339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Progress in Pharmacological and Surgical Management of Tourette Syndrome and Other Chronic Tic Disorders.</article-title>
            <source>Neurologist</source>
            <year>2019</year>
            <month>May</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>93</fpage>
            <page-range>93-108</page-range>
            <pub-id pub-id-type="pmid">31045720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seneviratne</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>EEG changes in patients on antipsychotic therapy: A systematic review.</article-title>
            <source>Epilepsy Behav</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>95</volume>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">30999157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Peikert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dobson-Stone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rampoldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miltenberger-Miltenyi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Neiman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Camilli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Monaco</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Danek</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title><italic>VPS13A</italic> Disease</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bean</surname>
                <given-names>LJH</given-names>
              </name>
              <name>
                <surname>Gripp</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2002</year>
            <month>6</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">20301561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Majumder</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Doifode</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kablinger</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?</article-title>
            <source>World J Psychiatry</source>
            <year>2021</year>
            <month>Dec</month>
            <day>19</day>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>1228</fpage>
            <page-range>1228-1238</page-range>
            <pub-id pub-id-type="pmid">35070772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Anzia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lyness</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mojtabai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Servis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walaszek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenzenweger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <collab>(Systematic Review)</collab>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>177</volume>
            <issue>9</issue>
            <fpage>868</fpage>
            <page-range>868-872</page-range>
            <pub-id pub-id-type="pmid">32867516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blair</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Lumateperone: First Approval.</article-title>
            <source>Drugs</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>417</fpage>
            <page-range>417-423</page-range>
            <pub-id pub-id-type="pmid">32060882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Winhofer-St&#x000f6;ckl</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kazemi-Shirazi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hofer</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Brath</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sourij</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vila</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abrahamian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weitgasser</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Resl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clodi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luger</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Other specific types of diabetes and exocrine pancreatic insufficiency (Update 2019)].</article-title>
            <source>Wien Klin Wochenschr</source>
            <year>2019</year>
            <month>May</month>
            <volume>131</volume>
            <issue>Suppl 1</issue>
            <fpage>16</fpage>
            <page-range>16-26</page-range>
            <pub-id pub-id-type="pmid">30980164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schultz</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kamholz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Nopoulos</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Killoran</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparing Risperidone and Olanzapine to Tetrabenazine for the Management of Chorea in Huntington Disease: An Analysis from the Enroll-HD Database.</article-title>
            <source>Mov Disord Clin Pract</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-138</page-range>
            <pub-id pub-id-type="pmid">30838312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Javaheri</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>McLennan</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Adherence to Antipsychotic Adverse Effect Monitoring Among a Referred Sample of Children with Intellectual Disabilities.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-240</page-range>
            <pub-id pub-id-type="pmid">30810348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Boushra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagalli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Neuroleptic Agent Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">32119495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cusimano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>VandenBerg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Long-acting injectable antipsychotics and their use in court-ordered treatment: A cross-sectional survey of psychiatric pharmacists' perceptions.</article-title>
            <source>Ment Health Clin</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-24</page-range>
            <pub-id pub-id-type="pmid">31942274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Antipsychotic Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalal</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Kar</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Management of Psychiatric Disorders in Patients with Chronic Kidney Diseases.</article-title>
            <source>Indian J Psychiatry</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>Suppl 2</issue>
            <fpage>S394</fpage>
            <page-range>S394-S401</page-range>
            <pub-id pub-id-type="pmid">35602366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Olanzapine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30000115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uguz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>244</fpage>
            <page-range>244-52</page-range>
            <pub-id pub-id-type="pmid">27028982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edinoff</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Sathivadivel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McNeil</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Ly</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Kweon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kelkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic Use in Pregnancy: Patient Mental Health Challenges, Teratogenicity, Pregnancy Complications, and Postnatal Risks.</article-title>
            <source>Neurol Int</source>
            <year>2022</year>
            <month>Jan</month>
            <day>03</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-74</page-range>
            <pub-id pub-id-type="pmid">35076595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Betcher</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Montiel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Use of Antipsychotic Drugs During Pregnancy.</article-title>
            <source>Curr Treat Options Psychiatry</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-31</page-range>
            <pub-id pub-id-type="pmid">32775146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Thackray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lubsch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hellinga</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title><italic>K</italic>ey Potentially <italic>I</italic>nappropriate <italic>D</italic>rugs in Pediatrics: The KIDs List.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-191</page-range>
            <pub-id pub-id-type="pmid">32265601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotlinska-Lemieszek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klepstad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Haugen</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Clinically Significant Drug-Drug Interactions Involving Medications Used for Symptom Control in Patients With Advanced Malignant Disease: A Systematic Review.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2019</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>989</fpage>
            <page-range>989-998.e1</page-range>
            <pub-id pub-id-type="pmid">30776538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Malortie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cronqvist</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ringb&#x000e4;ck</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Flyckt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bodlund</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Msghina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[New national guidelines for the treatment of schizophrenia in Sweden].</article-title>
            <source>Lakartidningen</source>
            <year>2019</year>
            <month>Jan</month>
            <day>28</day>
            <volume>116</volume>
            <pub-id pub-id-type="pmid">30694520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Velaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Werneke</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Reducing the stigma of long acting injectable antipsychotics - current concepts and future developments.</article-title>
            <source>Nord J Psychiatry</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>72</volume>
            <issue>sup1</issue>
            <fpage>S36</fpage>
            <page-range>S36-S39</page-range>
            <pub-id pub-id-type="pmid">30688170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shad</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Felzien</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>How to identify and manage non-response to clozapine?</article-title>
            <source>Asian J Psychiatr</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>45</volume>
            <fpage>50</fpage>
            <page-range>50-52</page-range>
            <pub-id pub-id-type="pmid">31494348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sidor</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>MacQueen</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>An update on antidepressant use in bipolar depression.</article-title>
            <source>Curr Psychiatry Rep</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>696</fpage>
            <page-range>696-704</page-range>
            <pub-id pub-id-type="pmid">23065437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ganz</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fenton</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hartry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gwin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fillit</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia.</article-title>
            <source>JAMA Netw Open</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>e203630</fpage>
            <pub-id pub-id-type="pmid">32343351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seebaluck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Downes</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Isoardi</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Case series profile of olanzapine post-injection delirium/sedation syndrome.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>89</volume>
            <issue>2</issue>
            <fpage>903</fpage>
            <page-range>903-907</page-range>
            <pub-id pub-id-type="pmid">36349832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nachmani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Drugs that Can Kill a Toddler with One Tablet or Teaspoonful: A 2018 Updated List.</article-title>
            <source>Clin Drug Investig</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <page-range>217-220</page-range>
            <pub-id pub-id-type="pmid">30443871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Fatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction.</article-title>
            <source>Forensic Sci Med Pathol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-113</page-range>
            <pub-id pub-id-type="pmid">30498933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ware</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Feller</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic Malignant Syndrome: Diagnosis and Management.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2018</year>
            <month>Jan</month>
            <day>04</day>
            <volume>20</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29325237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ngo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guerrero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanum</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burgett-Moreno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fenati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neeki</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Emergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using Dantrolene.</article-title>
            <source>Clin Pract Cases Emerg Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-23</page-range>
            <pub-id pub-id-type="pmid">30775657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Limandri</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Long-Acting Injectable Antipsychotic Medications: Why Aren't They Used as Often as Oral Formulations?</article-title>
            <source>J Psychosoc Nurs Ment Health Serv</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>7</fpage>
            <page-range>7-10</page-range>
            <pub-id pub-id-type="pmid">30835795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25800.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakanishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koyama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Higuchi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Nurses' collaboration with physicians in managing medication improves patient outcome in acute psychiatric care.</article-title>
            <source>Psychiatry Clin Neurosci</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-203</page-range>
            <pub-id pub-id-type="pmid">16594944</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
